Geodon (ziprasidone), a new atypical antipsychotic for schizophrenia

March 2001

Pfizer will soon market Geodon (ziprasidone), a new atypical antipsychotic for schizophrenia.

Geodon will be widely used because it appears to cause less weight gain than other atypicals...Zyprexa, Risperdal, or Seroquel.

Weight gain causes some patients to discontinue therapy...and it increases the risk of developing diabetes and heart disease.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

infections might play a significant role in many chronic diseases
Gastroenterology Nexium, a follow-up to their Prilosec proton pump inhibitor
Women's Health NSAIDs during pregnancy
acetylcysteine (Mucomyst) can help prevent renal damage from IV contrast dyes
Antipsychotics Geodon (ziprasidone), a new atypical antipsychotic for schizophrenia
Infectious Diseases if the Lyme vaccine triggers severe arthritis in some patients
Infectious Diseases Cancidas (can-SIGH-das, caspofungin), a new IV antifungal
Supplements new concerns about the safety of kava
potential for mix-ups between Depakote ER and the original Depakote (divalproex) tablets
Provigil (modafinil) for depression
Hepatitis C Trental (pentoxifylline) is beneficial for patients with severe alcoholic hepatitis
garlic supplements can interact with HIV protease inhibitors
new thinking on when to start HIV therapy
Vaccines parents' misconceptions about immunizations